Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis

References

• Ruderman EM. The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis. Bull Hosp Jt Dis 2013;71:S29–32.
   Google Scholar
• Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51:1368–77.
   PubMed Web of Science ®Google Scholar
• Behrens F, Cañeta JD, Olivieri I, van Kuijk AW, McHugh N, Combe B. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford) 2015;54:915–26.
   PubMed Web of Science ®Google Scholar
• Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2013;73:132–7.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Østergaard M, Dreyer L, Krogh NS, Tarp U, Hansen S, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy. Arthritis Rheum 2011;63:382–90.
   PubMed Web of Science ®Google Scholar
• Behrens F, Koehm M, Arndt U, Wittig BM, Greger G, Thaçi D, et al. Does concomitant methotrexate impact treatment outcomes with adalimumab in psoriatic arthritis patients? An in-depth analysis of data from a large observational study. J Rheumatol 2016;43:632–9.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open 2015;1:e000181.
   PubMed Web of Science ®Google Scholar
• Kleinert S, Tony H-P, Krause A, Feuchtenberger M, Wassenberg S, Richter C, et al. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study. Rheumatol Int 2012;32:2759–67.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ‘T Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van Den Bosch F, et al. DAS28 best reflects the physician‘s clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005;7:R1063–71.
   PubMed Web of Science ®Google Scholar
• Ujfalussy I, Koo E. [Measurement of disease activity in psoriatic arthritis: extended report], in German. Z Rheumatol 2003;62:60–5.
   PubMed Web of Science ®Google Scholar
• Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;35:1373–8.
   Web of Science ®Google Scholar
• Khan NA, Spencer HJ, Abda E, Aggarwal A, Altern R, Ancuta C, et al. Determinants of discordance in patients’ and physicians’ rating of rheumatoid arthritis disease activity. Arthritis Care Res 2012;64:206–14.
   PubMed Web of Science ®Google Scholar
• Scharbatke EC, Behrens F, Schmalzing M, Koehm M, Greger G, Gnann H, et al. Association of improvement in pain with therapeutic response as determined by individual improvement criteria in patients with rheumatoid arthritis. Arthritis Care Res 2016;68:1607–15.
   Web of Science ®Google Scholar
• Lautenschläger J, Mau W, Kohlmann T, Raspe HH, Struve F, Brückle W, et al. Comparative evaluation of a German version of the health assessment questionnaire and the hannover functional capacity questionnaire. Z Rheumatol 1997;56:144–55.
   PubMed Web of Science ®Google Scholar
• Raspe HH, Hagedorn U, Kohlmann T, Mattussek S. In: Siegrist J, editor. Wohnortnahe Betreuung Rheumakranker. Ergebnisse sozialwissenschaftlicher evaluation eines Modellversuches. Stuttgart: Schattauer. 1990:164–82.
   Google Scholar
• Mease PJ. Measures of psoriatic arthritis. Arthritis Care Res 2011;63:S64–85.
   PubMed Web of Science ®Google Scholar
• Spuls PI, Leculse LLA, Poulsen MLNF, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2010;130:933–43.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385–90.
   PubMed Web of Science ®Google Scholar
• Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. A multinational, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2004;50:1939050.
   Web of Science ®Google Scholar
• Ballegaard C, Højgaard P, Dreyer L, Cordtz R, Jørgensen TS, Skougaard M, et al. Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 2018;70:592–9.
   PubMed Web of Science ®Google Scholar
• Leeb BF, Andel I, Sautner J, Fassl C, Nothnagl T, Rintelen B. The disease activity score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum 2007;57:256–60.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Samad AS, Coates LC, Liu LXH, Aras GA, et al. Design and rationale of the study of etanercept and methotrexate in combination or as monotherapy in subjects with psoriatic arthritis (SEAM-PsA). RMD Open 2018;4:e000606.
   PubMed Web of Science ®Google Scholar
• De Marco G, Helliwell P, McGonagle D, Emergy P, Coates LC, Hensor EMA, et al. The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. BMC Musculoskeletal Disord 2017;18:303.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled, phase 3 trial. Arthritis Rheumatol. Published online: 12 February 2019. doi:10.1002/art.40851.
   Web of Science ®Google Scholar
• Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, et al. Two-year survival rates of anti-TNF-ɑ therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol 2015;44:192–9.
   PubMed Web of Science ®Google Scholar